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Ovarian cancerAbstract Background: Brivanib is a selective inhibitor of vascular endothelial growth factor
and fibroblast growth factor (FGF) signalling. We performed a phase II randomised discon-
tinuation trial of brivanib in 7 tumour types (soft-tissue sarcomas [STS], ovarian cancer, breast
cancer, pancreatic cancer, non-small-cell lung cancer [NSCLC], gastric/esophageal cancer and
transitional cell carcinoma [TCC]).
Patients and methods: During a 12-week open-label lead-in period, patients received brivanib
800 mg daily and were evaluated for FGF2 status by immunohistochemistry. Patients with sta-
ble disease at week 12 were randomised to brivanib or placebo. A study steering committee
evaluated week 12 response to determine if enrolment in a tumour type would continue.
The primary objective was progression-free survival (PFS) for brivanib versus placebo in pa-
tients with FGF2-positive tumours.
Results: A total of 595 patients were treated, and stable disease was observed at the week 12
randomisation point in all tumour types. Closure decisions were made for breast cancer,
pancreatic cancer, NSCLC, gastric cancer and TCC. Criteria for expansion were met for
STS and ovarian cancer. In 53 randomised patients with STS and FGF2-positive tumours,
the median PFS was 2.8 months for brivanib and 1.4 months for placebo (hazard ratio
[HR]: 0.58, p Z 0.08). For all randomised patients with sarcomas, the median PFS was 2.8
months (95% confidence interval [CI]: 1.4e4.0) for those treated with brivanib compared with
1.4 months (95% CI: 1.3e1.6) for placebo (HRZ 0.64, 95% CI: 0.38e1.07; pZ 0.09). In the
36 randomised patients with ovarian cancer and FGF2-positive tumours, the median PFS was
4.0 (95% CI: 2.6e4.2) months for brivanib and 2.0 months (95% CI: 1.2e2.7) for placebo (HR:
0.56, 95% CI: 0.26e1.22). For all randomised patients with ovarian cancer, the median PFS in
those randomised to brivanib was 4.0 months (95% CI: 2.6e4.2) and was 2.0 months (95% CI:
1.2e2.7) in those randomised to placebo (HR Z 0.54, 95% CI: 0.25e1.17; p Z 0.11).
Conclusion: Brivanib demonstrated activity in STS and ovarian cancer with an acceptable
safety profile. FGF2 expression, as defined in the protocol, is not a predictive biomarker of
the efficacy of brivanib.
ª 2019 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Brivanib is a small-molecule inhibitor of the vascular
endothelial growth factor (VEGF) and fibroblast
growth factor (FGF) family of tyrosine kinase receptors
[1,2]. The FGF pathway is involved in cell proliferation,
differentiation, survival, angiogenesis and wound heal-
ing [3]. A variety of specific abnormalities of the FGF
pathway (mutations, translocations, amplifications and
overexpression) exist in multiple solid tumours [3]. A
retrospective analysis of a phase I trial of brivanib
suggested that patients with tumours expressing FGF2
by immunohistochemistry (IHC) were more likely to
benefit from therapy [4].
The randomised discontinuation trial (RDT) is an
approach to evaluate cytostatic drugs, incorporating a
lead-in phase in which all patients are treated with the
test drug, and was pivotal in the development of sor-
afenib for renal cell carcinoma [5,6]. Patients with dis-
ease progression after the lead-in phase withdraw fromthe trial and those with a partial response (PR) continue
on test drugs. Patients with stable disease (SD) at the
end of the lead-in phase are then randomised to receive
the test drug or placebo [7]. This design has a number of
advantages as all enrolled patients receive the test drug
leading to rapid accrual [7].
We performed a randomised discontinuation phase II
trial to evaluate the efficacy and safety of brivanib in
multiple tumour types based on their known expression
of FGF2 (soft-tissue sarcomas [STS], ovarian cancer,
breast cancer, pancreatic cancer, non-small-cell lung
cancer [NSCLC], gastric/esophageal cancer and transi-
tional cell carcinoma [TCC]) and hypothesised that
FGF2 overexpression would be predictive of efficacy [4].2. Patients and methods
This trial was approved by the institutional review
board or ethics committee at each participating centre
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was conducted according to Good Clinical Practice
guidelines, the Declaration of Helsinki and local laws.
All patients provided written informed consent.
The study enrolled 7 tumour types: STS, ovarian
cancer, breast cancer, pancreatic cancer, NSCLC,
gastric/esophageal cancer and TCC. Eligible patients
had a histologically or cytologically confirmed diagnosis
of one of the eligible tumours (unresectable or meta-
static) for which no approved therapy was available.
Other key inclusion criteria were as follows: an Eastern
Cooperative Oncology Group performance status (PS)
of 0e1, at least 3 weeks since the last dose of anticancer
therapy, and adequate renal, hepatic and bone marrow
function. A tumour sample (archival block) evaluable
for FGF2 expression was required for randomisation.
This phase II RDT consisted of a 12-week lead-in
period, during which all patients received oral, open-
label brivanib 800 mg once daily. At week 12, patients
with SD were randomised 1:1 to receive either brivanib
or placebo. Unblinding was permitted when disease
progression was documented, and patients on placebo
could then cross over to brivanib. A maximum of 2 dose
reductions was permitted on the trial (to 400 mg daily),
and no re-escalation was allowed.
A study steering committee (SSC) reviewed and made
changes as needed during the trial. The SSC reviewed
accrual, FGF2 expression frequency and tumour
response at the end of the lead-in phase (week 12) and
determined if enrolment in a given tumour type would
continue.
The primary objective of this trial was to compare
progression-free survival (PFS) for brivanib versus pla-
cebo in randomised patients (in one or more selected
tumour types) with FGF2-positive tumours. PFS was
also analysed in all randomised patients, regardless of
FGF2 status. The secondary end-points included disease
stabilisation rate, objective response rate and safety.
Central review of FGF2 status by IHC was per-
formed based on criteria from a previous clinical trial
[8]. Tumours were classified as FGF2 positive if the
expression score was 1, 2 or 3 and negative if the
expression score was 0. Analysis for correlation between
grading intensity and efficacy was not performed.
Radiological response was evaluated every 6 weeks.
For randomised patients, response was evaluated every
6 weeks up to week 36 and subsequently every 12 weeks.
Radiological response was evaluated according to
modified World Health Organization criteria using
bidimensional measurements [5]. Complete response or
PR was confirmed by a second tumour assessment 4
weeks or more after the response was first documented.
Safety assessments were performed on all patients for
the entire treatment period. Adverse events (AEs) and
laboratory values were graded according to National
Cancer Institute Common Terminology Criteria
(version 3.0).2.1. Statistical methods
The primary analysis was the comparison of PFS be-
tween brivanib and placebo in the randomised FGF2-
positive cohort. This comparison was performed sepa-
rately for each tumour type (that was selected for
expansion) using a 2-sided 10% level log-rank test with
80% power. No adjustment was made for multiple
testing. Fifty-two events were required to detect a haz-
ard ratio of 0.5, corresponding to a doubling in the
median PFS for brivanib compared with placebo (i.e.
2e4 months). Assuming that 70 patients with FGF2-
positive tumours were randomised during a 16-month
period, 52 events were expected to be observed after 16
months.
The total number of randomised patients for the
primary analysis in the STS and ovarian cohorts was
lower than originally planned owing to the relatively
low FGF2 positivity rate. As the required number of
events in the FGF2-positive STS cohort was not
reached, the sample size requirements (52 events
required in the randomised period) were applied to the
overall population rather than to the FGF2-positive
population. Consequently, the statistical power of the
primary analysis was lower than 80%. The alternative
hypothesis around the effect size was made more strin-
gent, and PFS comparison was conducted on all rand-
omised patients (regardless of FGF2 status) to ensure
80% power.
Forty randomised patients with ovarian cancer
(regardless of FGF2 status) were required to reach 28
events when comparing PFS for brivanib and placebo at
a HR of 0.33, 2-sided alpha of 5% and power 80%.
The KaplaneMeier product-limit method was used
to estimate median PFS; its corresponding confidence
interval (CI) was compared by the method used by
Brockmeyer and Crowley [8]. For randomised patients,
HR with the corresponding CI was calculated using the
Cox proportional hazards model. Because all patients
received brivanib at the same initial dose, the safety
analysis was performed on the pooled population.3. Results
Between June 2008 and August 2011, 595 patients with
7 tumour types were treated with brivanib within the
phase II trial. The baseline characteristics of these pa-
tients are shown in Table 1. Most patients were female
(377, 63%), and 290 patients (49%) had a PS of 0. This
was a heavily pre-treated population, with 18% of pa-
tients having received 2 prior lines of systemic therapy
and 55% having received 3 lines of therapy. The
FGF2 status at the baseline and randomisation for all
tumour types are displayed in Table 2. Owing to
logistical issues, publication of this manuscript was
delayed.
Table 1
Baseline characteristics by tumour type.
Characteristic Tumour type Overall
(n Z 595)
STS
(n Z 251)
NSCLC
(n Z 42)
TCC
(n Z 31)
Gastric
cancer
(n Z 34)
Pancreatic
cancer
(n Z 38)
Ovarian
cancer
(n Z 126)
Breast
cancer
(n Z 73)
Mean (SD) age, years 54 (15) 64 (11) 61 (10) 60 (8) 58 (10) 58 (11) 73 (9) 57 (13)
Male gender, n (%) 177 (47) 24 (57) 25 (81) 25 (74) 27 (71) 0 0 218 (37)
Time from diagnosis 2 years, n (%) 154 (61) 30 (71) 13 (42) 10 (29) 11 (29) 101 (80) 71 (97) 390 (66)
ECOG PS, n (%)
0 143 (57) 7 (17) 12 (39) 10 (29) 13 (34) 59 (47) 46 (53) 290 (49)
1 107 (43) 34 (81) 19 (61) 23 (68) 25 (66) 65 (52) 27 (37) 300 (50)
Prior treatments, n (%)
Radiotherapy 132 (53) 21 (50) 13 (42) 15 (44) 12 (32) 14 (18) 57 (78) 264 (44)
Antiangiogenic therapy 27 (11) 16 (38) 2 (7) 2 (6) 0 15 (19) 19 (26) 81 (14)
Other systemic therapy 199 (79) 42 (100) 31 (100) 34 (100) 36 (95) 126 (100) 73 (100) 541 (91)
No. of prior systemic regimens, n (%)
0 50 (20) 0 0 0 2 (5) 0 0 52 (9)
1 71 (28) 3 (7) 15 (48) 10 (29) 11 (29) 11 (9) 0 112 (19)
2 47 (19) 7 (17) 11 (36) 11 (32) 13 (34) 19 (15) 1 (1) 109 (18)
 3 83 (33) 32 (76) 5 (16) 13 (38) 12 (32) 96 (76) 72 (99) 327 (55)
FGF2-positive by IHC, % (assessable
patients)
65 (142/
218)
79 (27/
34)
88 (22/
25)
97 (30/31) 79 (23/29) 89 (86/97) 79 (50/63) 76 (380/
497)
FGF, fibroblast growth factor; IHC, immunohistochemistry; ECOG, Eastern Cooperative Oncology Group; PS, performance status; STS, soft
tissue sarcomas; NSCLC, non-small-cell lung cancer; SD, stable disease; TCC, transitional cell carcinoma.
Table 2
FGF2 status at the baseline and randomisation and secondary efficacy end-points at the end of the lead-in period (week 12).
Tumour type Number of FGF2-positive patients/number of assessed patients (%)
Baseline Randomisation
Soft tissue sarcomas 142/218 (65%) 53/76 (70%)
Ovarian cancer 97/126 (77%) 36/39 (92%)
Breast cancer 50/63 (79%) 9/12 (75%)
Pancreatic cancer 23/29 (79%) 4/5 (80%)
Non-small-cell lung cancer 27/42 (79%) 7/11 (64%)
Gastric/esophageal carcinoma 30/31 (97%) 5/5 (100%)
Transitional cell carcinoma 22/25 (88%) 4/4 (100%)
Overall trial population 391/510 (77%) 118/152 (78%)
Tumour type Objective response rate Disease stabilisation rate Change in tumour size
Soft tissue sarcomas 2.8% (95% CI: 0.8e7.1) 28.9% (95% CI: 21.6e37.1) 40%a
Ovarian cancer 8.2% (95% CI: 3.6e15.6) 38.1% (95% CI: 28.5e48.6) NA
Breast cancer 8.2% (95% CI: 3.1e17.3) 20.5% (95% CI: 12.0e31.6) NA
Pancreatic cancer 0 13.2% (95% CI: 4.4e28.1) NA
Non-small-cell lung cancer 0 23.8% (95% CI: 12.1e39.5) NA
Gastric/esophageal cancer 8.8% (95% CI: 1.9e23.7) 8.8% (95% CI: 1.9e23.7) 75%b
Transitional cell carcinoma 0 16.1% (95% CI: 5.5e33.7) NA
FGF, fibroblast growth factor; CI, confidence interval.
a FGF2-positive treated patients.
b All but one patient was FGF2 positive.
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The randomisation rate (i.e. SD at week 12) for the
overall population was 30%. In addition, objective re-
sponses were observed in a number of disease cohorts
(Table 2), and these patients were continued on open-
label brivanib. The SSC regularly reviewed
KaplaneMeier estimates of the conditional probability
that a proportion of patients with a tumour type wouldreach the week 12 randomisation point before making a
decision whether to continue to accrue patients with
each tumour type. Closure decisions were made for the
breast cancer, pancreatic cancer, NSCLC, gastric cancer
and TCC tumour types based on evaluation by the SSC
(42 patients per tumour type). Therefore, the primary
end-point was not assessed in these tumours. The SSC
determined that the criteria for expansion were met for
STS and ovarian cancer.
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At the week 12 evaluation point, 7 patients with sar-
comas (2.8%) had a PR, 4 of these had FGF2-positive
tumours. Radiological responses were seen in angio-
sarcomas (n Z 3, Fig. 1), synovial, endometrial stro-
mal, follicular dendritic cell sarcomas and
leiomyosarcoma (1 each). Time to response ranged
from 1.1 to 2.8 months, and duration of response
ranged from 3.2 to 8.4 months.
Seventy-six patients (34%) had SD and were rando-
mised to receive brivanib (n Z 37) or placebo (n Z 36).
Three randomised patients were not treated, two had
Progressive disease (PD) at week 12 and were randomised
in error, and one patient with SD was not treated. In 53
randomised patients with FGF2-positive tumours, the
median PFS was 2.8 months for brivanib compared with
1.4 months for placebo (HR: 0.58, p Z 0.08), Fig. 2B.
For all randomised patients with sarcomas, the me-
dian PFS was 2.8 months (95% CI: 1.4e4.0) for those
treated with brivanib compared with 1.4 months (95%
CI: 1.3e1.6) for placebo (HR Z 0.64, 95% CI:
0.38e1.07; p Z 0.09, Fig. 2A).
Seventy-five percent of patients randomised to pla-
cebo progressed by their first (after randomisation) scan.
Among the 30 randomised patients whose disease pro-
gressed while on placebo and then crossed over to open-
label brivanib, the median PFS was 4.1 months (95% CI:
2.8e6.2) (Fig. 2C). Most patients (87%; 95% CI:
69.3e96.2) had disease restabilisation on retreatment
with brivanib. One additional brivanib-treated patient
achieved a PR in the randomised period.
3.3. Ovarian cancer
A total of 126 patients with ovarian cancer were treated.
At the week 12 randomisation point, 9 patients (8.2%)Fig. 1. Clinical responses to brivanibhad a PR, and 43 (34%) had SD. Thirty-nine patients
were randomised, 19 to brivanib and 20 to placebo.
In the 36 randomised patients with ovarian cancer
and FGF2-positive tumours, the median PFS was 4.0
months (95% CI: 2.6e4.2) for those treated with briva-
nib and 2.0 months (95% CI: 1.2e2.7) for those given
placebo (HR: 0.56, 95% CI: 0.26e1.22).
For all randomised patients with ovarian cancer, the
median PFS in those randomised to brivanib was 4.0
months (95% CI: 2.6e4.2) and was 2.0 months (95% CI:
1.2e2.7) in those randomised to placebo (HR Z 0.54,
95% CI: 0.25e1.17; p Z 0.11).
Three patients achieved a PR to brivanib during the
randomised period. The time to response for these pa-
tients was 6.7, 3.9 and 1.7 months.
Patients who crossed over from placebo to brivanib
had a subsequent median PFS of 1.5 months (95% CI:
1.2e2.8).
3.4. Entire trial population
A post hoc KaplaneMeier analysis was performed in all
randomised patients (n Z 152), irrespective of the
tumour type. The median PFS for all randomised pa-
tients (stratified by tumour type and FGF2 status) was
2.8 months (95% CI: 2.2e3.9) for patients treated with
brivanib and was 1.4 months (95% CI: 1.3e1.8) for
those on placebo (HR: 0.6, 95% CI: 0.41e0.88). An
unstratified analysis of all randomised patients showed
similar results.
3.5. Safety
AEs (regardless of causality) that occurred in 10% of
the overall trial population are shown in Table 3. The
most common AEs (>25% of patients) were fatigue,
nausea, vomiting, decreased appetite, hypertension andin patients with angiosarcoma.
Fig. 2. KaplaneMeier curves of progression-free survival in all randomised patients with soft tissue sarcomas (A), patients with FGF2-
positive tumours (B) and randomised patients with progression on placebo and treated with brivanib (C). FGF, fibroblast growth factor.
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for >5% of patients, regardless of causality) were hy-
pertension, fatigue, increased alanine aminotransferase,
increased aspartate aminotransferase, dyspnoea, malig-
nant neoplasm and abdominal pain.
AEs leading to discontinuation were reported for 143
(24%) patients. The most common AEs leading to
discontinuation were disease progression (12/143, 8%),
vomiting (11/143, 8%) and dyspnoea (11/143, 8%).
Serious AEs (SAEs) were reported for 45% of treated
patients. The most common SAEs (2%, regardless of
causality) were malignant neoplasm, vomiting, dehy-
dration, dyspnoea, hypertension, abdominal pain and
nausea.Sixty-eight patients (11%) died within 30 days of the
last dose of brivanib. The primary cause of death was
disease progression (51/68, 75%). In 6 patients (2 breast
cancer and 1 each of gastric cancer, ovarian cancer,
pancreatic cancer and NSCLC), the cause of death was
potentially drug toxicity, ascribed to multiorgan failure,
cerebral haemorrhage, hypovolemic shock due to
dissection of aortic aneurysm, intracranial haemor-
rhage, bowel perforation and pulmonary haemorrhage.4. Discussion
This randomised discontinuation phase II trial suggests
that brivanib may have activity in multiple solid
Table 3
Summary of adverse events (N Z 595).
Adverse event, n (%) All grades Grade IIIeV
Total patients with an event 591 (99) 423 (71)
Diarrhoea 301 (51) 276 (46)
Nausea 280 (47) 262 (44)
Vomiting 198 (33) 177 (30)
Constipation 131 (22) 124 (21)
Abdominal pain 118 (20) 85 (14)
Stomatitis 64 (11) 58 (10)
Fatigue 382 (64) 303 (51)
Asthenia 65 (11) 49 (8)
Alanine aminotransferase increase 103 (17) 33 (6)
Aspartate aminotransferase increase 99 (17) 54 (9)
Weight decrease 91 (15) 87 (15)
Decreased appetite 269 (45) 246 (41)
Back pain 85 (14) 78 (13)
Dizziness 181 (30) 176 (30)
Headache 148 (25) 140 (24)
Dyspnoea 101 (17) 68 (11)
Dysphonia 82 (14) 82 (14)
Cough 73 (12) 71 (12)
Hypertension 234 (39) 156 (26)
AEs, adverse events.
The list includes AEs (all grades, any relationship) that occurred in
10% of the treated patients pooled from 7 cohorts and AEs with
onset on or after the first dosing date and on or before the last dosing
date, þ14 days.
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conclusion is the improvement in PFS with brivanib
compared with placebo in patients randomised to
continuous brivanib. In patients with sarcomas, 75% of
those on placebo had disease progression after ran-
domisation, indicating that disease stabilisation during
the lead-in period was most likely due to brivanib and
reversed rapidly when the treatment ended. Further
evidence of activity was provided by patients whose
disease progressed while on placebo and received bri-
vanib during the crossover period, with a median PFS of
4.1 months and SD rate of 87%, suggesting that inter-
ruption of brivanib did not interfere with responsiveness
to subsequent treatment. Temporary withdrawal of
brivanib could lead to greater activity than continuous
dosing, by allowing re-engagement of the angiogenesis
process. Alternatively, a greater percentage of patients
randomised to placebo were actually benefitting from
the drug (relative to those randomised to brivanib).
In certain subtypes such as angiosarcomas, synovial
sarcomas, chondrosarcoma and fibrosarcoma, three-
month PFS rates exceeded 50%, indicating the activity
of brivanib in these subtypes [9]. To put these results in
perspective, the PFS rate in the current trial is similar to
that reported in a phase II trial of pazopanib [10,11].
Furthermore, a randomised trial of maintenance pazo-
panib, following first-line therapy in ovarian cancer,
reported an improvement in median PFS for pazopanib
compared with 5.6 months for placebo [12]. In our trial,
the median PFS for all randomised patients with
ovarian cancer treated with brivanib was 4 months.The results of our trial and the role of the VEGF and
FGF pathways in the biology of sarcomas suggest that
brivanib should be further evaluated. It is unclear
whether the activity of brivanib is due to inhibition of
the vascular endothelial growth factor receptor
(VEGFR) or FGF receptor (FGFR). As the FGF
pathway has a potential role as a mediator of resistance
to VEGFR inhibitors, the simultaneous inhibition of the
VEGFR/FGFR is rational [13].
In addition, objective responses were observed in
ovarian, breast and gastric/esophageal cancer. Activated
mutations of FGFR3 occur in 38e66% of non-invasive
and in 15e20% of invasive urothelial cancer, with oc-
casional observation of FGFR gene fusions [14,15]. The
pan-FGFR inhibitor, erdafitinib, has been approved for
FGFR-mutated urothelial carcinoma [16].
FGF2 expression, as defined in the protocol, did not
appear to be a biomarker that could be used to select
patients with responsive tumours. This was supported
by several lines of evidence. First, the median PFS was
similar in the FGF2-positive population and all treated
patients, regardless of FGF2 status. Second, the pro-
portion of FGF-positive patients at baseline was similar
to that at randomisation. A better understanding of the
FGF pathway may help to identify other markers of
FGF dependence.5. Conclusion
This randomised discontinuation phase II trial suggests
that brivanib may have activity in STS and ovarian
cancer. This trial showed that FGF2 expression is not a
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